Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the fourth quarter an...
Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
I am returning from a writing break to once again cover the stock that I have both followed and written about for the longest period of time, Cytokinetics ( CYTK ). Cytokinetics is a developmental biotech which has been working in the area of muscle biology for over 20 years. Unfortunately, th...
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Duke Energy Corporation (NYSE:DUK), VICI Properties Inc. (NYSE:VICI), ...
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as ...
MyoKardia (NASDAQ: MYOK ) announces that its four-year collaboration with Sanofi (NYSE: SNY ) aimed at hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) ended on December 31, 2018. The partnership will formally conclude on April 1 with MYOK regaining global rights to ...
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered unde...
MyoKardia (NASDAQ: MYOK ): Q3 GAAP EPS of -$0.39 beats by $0.11 . More news on: MyoKardia, Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018....
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced today announced that Jake Bauer, Chief Business Officer,...
News, Short Squeeze, Breakout and More Instantly...
EXPLORER -HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten T reatment Resulted in Favorable Effect on Cardiac Structure -- Significantly Reduced Hypertrophy in Patien...
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with ...
BRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovas...